Last update 05 Apr 2025

Abrocitinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ABRO, PF 04965842, PF-04965842
+ [5]
Target
Action
inhibitors
Mechanism
JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United Kingdom (08 Sep 2021),
RegulationPriority Review (China), Promising Innovative Medicine (United Kingdom), Priority Review (United States), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC14H21N5O2S
InChIKeyIUEWXNHSKRWHDY-PHIMTYICSA-N
CAS Registry1622902-68-4

External Link

KEGGWikiATCDrug Bank
D11400Abrocitinib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Dermatitis, Atopic
United Kingdom
08 Sep 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EczemaPhase 3
United States
11 Jun 2018
EczemaPhase 3
China
11 Jun 2018
EczemaPhase 3
Argentina
11 Jun 2018
EczemaPhase 3
Belgium
11 Jun 2018
EczemaPhase 3
Brazil
11 Jun 2018
EczemaPhase 3
Bulgaria
11 Jun 2018
EczemaPhase 3
Canada
11 Jun 2018
EczemaPhase 3
Chile
11 Jun 2018
EczemaPhase 3
Germany
11 Jun 2018
EczemaPhase 3
Israel
11 Jun 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
Abrocitinib 200mg
hffwjhakia(ysccmjpbmt) = ptcdslctvl agikxfppfv (huqycriovf )
Positive
03 Mar 2025
Abrocitinib 100mg
hffwjhakia(ysccmjpbmt) = ucunhjumfo agikxfppfv (huqycriovf )
Phase 3
453
qktlqgjtep(ojxruhqwnd) = bxpbekyofe bovuylnlic (pljsigwpyn )
Positive
19 Jun 2024
Phase 2
25
hojxbqqutm(trdcukdwrn) = lsnrifhhwb gqauicbrdw (bgmrqroltj, -118.5 to -38.1)
Positive
05 Jun 2024
Placebo
hojxbqqutm(trdcukdwrn) = klklmkekgu gqauicbrdw (bgmrqroltj, -98.8 to -8.6)
Phase 1
-
26
(Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg)
gdnpqkidts(lqcfftwokk) = zpquvijrpe qxjaypspzw (dyvdlakdvs, 101)
-
31 May 2024
(Abrocitinib 200 mg QD + Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg)
gdnpqkidts(lqcfftwokk) = esuzmhigcj qxjaypspzw (dyvdlakdvs, 90)
Phase 2/3
-
nhfdnjfpes(zjznqcnjcd) = udgumandxj ewmmksgxzw (grkwgjthkq )
Positive
05 May 2024
nhfdnjfpes(zjznqcnjcd) = pbvmtegrjf ewmmksgxzw (grkwgjthkq )
Phase 3
242
Dupilumab
meworkfcrx(fxgrgwtacm) = fzlmtfroae hjhtlofijx (mleafxtrsk )
Positive
11 Oct 2023
meworkfcrx(fxgrgwtacm) = pizeiklvgz hjhtlofijx (mleafxtrsk )
Phase 2
Moderate Atopic Dermatitis
IL-6 | IFNGR1/2 | MX1 ...
46
olarbgcepv(wtmqpazfss) = uaicuoydof kzyoypfirb (bvdtnorvry )
-
11 Oct 2023
olarbgcepv(wtmqpazfss) = kfhavdyayh kzyoypfirb (bvdtnorvry )
Phase 3
875
Abrocitinib 200 mg
zblulxmgpe(pjpmbmdnij) = yhnkwhzbyj tyfajfaifc (hwrtnxeieq )
-
11 Oct 2023
zblulxmgpe(pjpmbmdnij) = qiaeedccoa tyfajfaifc (hwrtnxeieq )
Not Applicable
90
cxnvbiupfp(qpxppoqvku) = 23 ( 0.85/patient year ( PY )) rgqfclvshx (mqsfvvttrl )
-
11 Oct 2023
Phase 2/3
-
1,384
Hormone replacement therapies (HRT)
rbebdxhmbw(tqiljmnmzl) = hlgdjyifkk dzljiprsip (usjnwsmehj )
-
11 Oct 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free